Advertisement

Topics

Roche secures FDA priority review for entrectinib and polatuzumab vedotin

02:58 EST 20 Feb 2019 | Pharmaceutical Business Review

Entrectinib has been granted priority review for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors in adult and paediatric patients. The

The post Roche secures FDA priority review for entrectinib and polatuzumab vedotin appeared first on Pharmaceutical Business review.

Original Article: Roche secures FDA priority review for entrectinib and polatuzumab vedotin

NEXT ARTICLE

More From BioPortfolio on "Roche secures FDA priority review for entrectinib and polatuzumab vedotin"

Advertisement
Quick Search
Advertisement
Advertisement